EZH2: A pleiotropic protein

Abstract

In this issue of Blood, Yan et al report their findings in natural killer/T-cell lymphoma (NKTL) and present experimental evidence that EZH2 can act as a transcriptional activator, independent of its methyltransferase activity, when phosphorylated by JAK3. This may open up the prospect of new treatment options for a variety of neoplasms, where EZH2 is known to be involved.